U-M researchers developing the first microbiome-based oral nanomedicine that boosts cancer immunotherapy in mice

PHILADELPHIA, PA – Previously, the primary endpoint results of the NRG-LU005 (NCT03811002) study assessing the addition of the immunotherapy drug atezolizumab (Tecentriq®) to standard of care concurrent chemoradiation for limited-stage small cell lung cancer were reported at the American Society for Radiation Oncology 2024 Annual Meeting. Those results showed that adding atezolizumab did not improve overall survival (OS) for this patient population.   At the same time, an exploratory analysis reported a longer median OS among patients who received twice-a-day radiation, though the RT schedule was not randomized. As a follow up to that study, a patient-reported outcomes (PRO) analysis explored the impact of the NRG-LU005 treatment regimens on quality of life (QOL). The results of this PRO analysis are now published in the Journal of Thoracic Oncology after previously being reported as a late-breaking abstract at the ASTRO 2025 Annual Meeting in San Francisco, California.

Researchers have created one of the most detailed maps to date of how white blood cells called B cells develop and behave inside melanoma tumours, a type of skin cancer.Researchers have created one of the most detailed maps to date of how white blood cells called B cells develop and behave inside melanoma tumours, a type of skin cancer.